73 related articles for article (PubMed ID: 36622698)
1. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
Lakhani NJ; Rasco D; Wang H; Men L; Liang E; Fu T; Collins MC; Min P; Yin Y; Davids MS; Yang D; Zhai Y
Clin Cancer Res; 2024 Feb; 30(3):506-521. PubMed ID: 37971712
[TBL] [Abstract][Full Text] [Related]
2. BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation.
Yu CY; Yeung TK; Fu WK; Poon RYC
Cell Death Dis; 2024 Jan; 15(1):2. PubMed ID: 38172496
[TBL] [Abstract][Full Text] [Related]
3. Dynamic BH3 profiling identifies pro-apoptotic drug combinations for the treatment of malignant pleural mesothelioma.
Potter DS; Du R; Bohl SR; Chow KH; Ligon KL; Bueno R; Letai A
Nat Commun; 2023 May; 14(1):2897. PubMed ID: 37210412
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL targeting eliminates ageing tumor-promoting neutrophils and inhibits lung tumor growth.
Bodac A; Mayet A; Rana S; Pascual J; Bowler AD; Roh V; Fournier N; Craciun L; Demetter P; Radtke F; Meylan E
EMBO Mol Med; 2024 Jan; 16(1):158-184. PubMed ID: 38177532
[TBL] [Abstract][Full Text] [Related]
5. Kinetic Heterogeneity of Cancer Cell Fractional Killing.
Inde Z; Forcina GC; Denton K; Dixon SJ
Cell Rep; 2020 Jul; 32(1):107845. PubMed ID: 32640215
[TBL] [Abstract][Full Text] [Related]
6. Sequential apoptotic and multiplexed proteomic evaluation of single cancer cells.
Lecky E; Mukherji A; German R; Antonellis G; Lin JR; Yorsz M; McQueeney KE; Ryan J; Ng K; Sicinska E; Sorger PK; Letai A; Bhola PD
Sci Adv; 2023 Jun; 9(25):eadg4128. PubMed ID: 37352344
[TBL] [Abstract][Full Text] [Related]
7. Drug repurposing screening and mechanism analysis based on human colorectal cancer organoids.
Mao Y; Wang W; Yang J; Zhou X; Lu Y; Gao J; Wang X; Wen L; Fu W; Tang F
Protein Cell; 2024 Apr; 15(4):285-304. PubMed ID: 37345888
[TBL] [Abstract][Full Text] [Related]
8. Tolerance to colibactin correlates with homologous recombination proficiency and resistance to irinotecan in colorectal cancer cells.
Sogari A; Rovera E; Grasso G; Mariella E; Reilly NM; Lamba S; Mauri G; Durinikova E; Vitiello PP; Lorenzato A; Avolio M; Piumatti E; Bonoldi E; Aquilano MC; Arena S; Sartore-Bianchi A; Siena S; Trusolino L; Donalisio M; Russo M; Di Nicolantonio F; Lembo D; Bardelli A
Cell Rep Med; 2024 Feb; 5(2):101376. PubMed ID: 38228147
[TBL] [Abstract][Full Text] [Related]
9. Combined inhibition of Bcl-2 family members and YAP induces synthetic lethality in metastatic gastric cancer with RASA1 and NF2 deficiency.
Kwon JW; Oh JS; Seok SH; An HW; Lee YJ; Lee NY; Ha T; Kim HA; Yoon GM; Kim SE; Oh PR; Lee SH; Voon DC; Kim DY; Park JW
Mol Cancer; 2023 Sep; 22(1):156. PubMed ID: 37730636
[TBL] [Abstract][Full Text] [Related]
10. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
[TBL] [Abstract][Full Text] [Related]
11. Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer.
Goodwin CM; Rossanese OW; Olejniczak ET; Fesik SW
Cell Death Differ; 2015 Dec; 22(12):2098-106. PubMed ID: 26045046
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer.
Leto SM; Ferri M; Sassi F; Zanella ER; Cottino F; Vurchio V; Catalano I; Ferrero A; Zingaretti CC; Marchiò C; Grassi E; Trusolino L; Bertotti A
Clin Cancer Res; 2023 Mar; 29(6):1102-1113. PubMed ID: 36622698
[TBL] [Abstract][Full Text] [Related]
13. EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma.
Nalluri S; Peirce SK; Tanos R; Abdella HA; Karmali D; Hogarty MD; Goldsmith KC
Cancer Biol Ther; 2015; 16(2):276-86. PubMed ID: 25756510
[TBL] [Abstract][Full Text] [Related]
14. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
[TBL] [Abstract][Full Text] [Related]
15. Trichonomas vaginalis metalloproteinase induces apoptosis of SiHa cells through disrupting the Mcl-1/Bim and Bcl-xL/Bim complexes.
Quan JH; Kang BH; Cha GH; Zhou W; Koh YB; Yang JB; Yoo HJ; Lee MA; Ryu JS; Noh HT; Kwon J; Lee YH
PLoS One; 2014; 9(10):e110659. PubMed ID: 25343522
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
